A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
about
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureMethotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trialsSystemic methotrexate therapy for psoriasis: past, present and future.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm MeetingUse of biologic agents in combination with other therapies for the treatment of psoriasisMethotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature.Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical settingCurrent status and future prospects for biologic treatments of psoriasis.Biologics in dermatology.Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritisTherapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Biologic fatigue in psoriasis.Biological therapies for psoriasis.Systemic therapies for psoriasis: an evidence-based update.The risk of deep fungal infections during biologic therapy for psoriasis.Etanercept: a review of its use in autoimmune inflammatory diseases.The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.Systemic methotrexate for the treatment of psoriasis.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.The Inflammatory Response in Psoriasis: a Comprehensive Review.Review of maintenance of response to psoriasis treatments.A dermatologist guide to immunogenicityPredictors of long-term drug survival for infliximab in psoriasis.Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.Predictors of Topical Use in Psoriasis Patients in the REFINE Study.Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.Psoriatic erythroderma and hypothalamus-pituitary axis suppression due to misuse of systemic steroid: two challenging casesDrug survival of biologic treatments in psoriasis: a systematic review.Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.Topical application of a linoleic acid-ceramide containing moisturizer exhibit therapeutic and preventive benefits for psoriasis vulgaris: a randomized controlled trial.Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
P2860
Q27012134-B07CDBB4-C3DC-41C5-8112-CB88C1C1BC3DQ28085725-3982FC4A-FCB1-4692-A1DD-D4C8591F3FF8Q34356265-EF3E3033-EA90-43B1-BFD3-F48D6C23A60EQ34377347-FF8F4F4E-BE94-4C9C-82E4-BE51FD4EF4E0Q34553755-5E8156C5-4161-4136-8AB9-4BF3AC3C62ABQ34642567-AD5EA97D-BB8B-40FB-AC8B-B3D10F358AD3Q34743112-3CC9A3F8-85C0-4586-B1A2-3E2EDE36F93CQ36057909-E77B6964-B02E-4FAB-841D-785A8AF5FAD0Q37277398-8532EA80-E597-44A8-BF0B-480BC34A7DE3Q37620900-F93D114C-328D-4BC2-BCC3-D7928A399F87Q37724124-20FC9F7F-D7E8-4447-96CA-C2B8C532BE39Q38098466-8B7E9C6E-2F79-4028-9D2E-38F254C5A758Q38123192-8444B13A-488D-44B6-961F-F7B154B40781Q38155648-9228541A-AA8F-407C-8F4B-3869057EB450Q38185297-9941E3A9-4B34-45E2-938B-7C03B7321DBBQ38219217-699B529F-F2E0-46A9-9603-7631CCA2721AQ38230740-86495DF7-6C3B-4C8B-A451-39E503DA2A0FQ38235809-6824318E-854B-47E3-9298-08A2E29E211AQ38380882-558A0E09-2E59-4E4D-B803-BF1D795845C7Q38473460-3B5CBD4F-55A5-44D5-BB02-A9E1488CD7AAQ38792930-5E11BFB8-E5F3-4A62-9944-15B15683E289Q38836347-E28E7713-AB5E-4439-8D07-61E7F146D19DQ39297511-9E0715A9-2F17-433C-882D-E32506D1DB17Q39668241-0DE01403-0185-4B3A-8AAF-0CC00DD1810BQ40045451-CBC7C5F5-F7A7-4B3A-9619-1DFB185E1A95Q40584386-AF3D19E9-ACC7-434E-92A3-349F266F7312Q40964546-6E62F763-53D5-4D45-8FF7-1AE5A789D116Q42699058-3EE78145-B086-4D1D-8F85-683D665FA479Q46118586-672C38E9-88AA-4E70-A8EC-9B91343D8B7EQ46171462-173D29D4-8582-440A-AC1B-CBEC527E2556Q47260366-6F6F4DFC-5468-4472-A6B3-C9EE2BDD1CDDQ48368354-C7CFD172-709F-4FC0-B52C-498D06747896Q53374658-FE7EABEE-6A21-4049-BEBD-0A499C887781Q54940383-5BD07CF1-B45B-4941-AECD-C20C0722C1B0
P2860
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... te to severe plaque psoriasis.
@ast
A randomized, double-blind, pl ...... te to severe plaque psoriasis.
@en
type
label
A randomized, double-blind, pl ...... te to severe plaque psoriasis.
@ast
A randomized, double-blind, pl ...... te to severe plaque psoriasis.
@en
prefLabel
A randomized, double-blind, pl ...... te to severe plaque psoriasis.
@ast
A randomized, double-blind, pl ...... te to severe plaque psoriasis.
@en
P2093
P2860
P1476
A randomized, double-blind, pl ...... ate to severe plaque psoriasis
@en
P2093
A B Gottlieb
B E Strober
E H Z Thompson
G Kricorian
P Klekotka
R G Langley
P2860
P304
P356
10.1111/J.1365-2133.2012.11015.X
P407
P50
P577
2012-09-01T00:00:00Z